Lexaria Bioscience Corp.
LEXX
$1.35
-$0.34-20.12%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | 174.00K | 183.90K | 84.00K | 84.00K | 145.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 174.00K | 183.90K | 84.00K | 84.00K | 145.00K |
| Cost of Revenue | -- | 2.70K | 0.00 | -- | -- |
| Gross Profit | 174.00K | 181.20K | 84.00K | 84.00K | 145.00K |
| SG&A Expenses | 1.24M | 918.70K | 1.26M | 1.25M | 567.20K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.93M | 2.87M | 2.23M | 1.83M | 813.00K |
| Operating Income | -2.75M | -2.69M | -2.15M | -1.74M | -668.00K |
| Income Before Tax | -2.72M | -2.71M | -2.19M | -1.78M | -652.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.72M | -2.71M | -2.19M | -1.78M | -652.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 3.80K | 2.90K | 1.80K | 2.60K | 3.20K |
| Net Income | -2.71M | -2.70M | -2.18M | -1.78M | -649.50K |
| EBIT | -2.75M | -2.69M | -2.15M | -1.74M | -668.00K |
| EBITDA | -2.75M | -2.66M | -2.13M | -1.73M | -652.10K |
| EPS Basic | -0.15 | -0.16 | -0.14 | -0.13 | -0.06 |
| Normalized Basic EPS | -0.10 | -0.10 | -0.08 | -0.08 | -0.04 |
| EPS Diluted | -0.15 | -0.16 | -0.14 | -0.13 | -0.06 |
| Normalized Diluted EPS | -0.10 | -0.10 | -0.08 | -0.08 | -0.04 |
| Average Basic Shares Outstanding | 17.51M | 16.67M | 15.71M | 13.86M | 10.77M |
| Average Diluted Shares Outstanding | 17.51M | 16.67M | 15.71M | 13.86M | 10.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |